Takeda Pharmaceutical Company Limited
4502.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥6,967,566,549 | ¥6,506,547,550 | ¥6,750,369,150 | ¥5,469,126,498 |
| - Cash | ¥233,742,000 | ¥205,190,000 | ¥229,557,000 | ¥849,695,000 |
| + Debt | ¥5,088,590,000 | ¥5,463,391,000 | ¥4,861,692,000 | ¥4,810,649,000 |
| Enterprise Value | ¥11,822,414,549 | ¥11,764,748,550 | ¥11,382,504,150 | ¥9,430,080,498 |
| Revenue | ¥4,581,551,000 | ¥4,263,762,000 | ¥4,027,478,000 | ¥3,569,006,000 |
| % Growth | 7.5% | 5.9% | 12.8% | – |
| Gross Profit | ¥2,455,188,000 | ¥2,324,911,000 | ¥2,298,316,000 | ¥2,043,633,000 |
| % Margin | 53.6% | 54.5% | 57.1% | 57.3% |
| EBITDA | ¥1,127,443,000 | ¥927,954,000 | ¥1,184,514,000 | ¥1,042,820,000 |
| % Margin | 24.6% | 21.8% | 29.4% | 29.2% |
| Net Income | ¥107,928,000 | ¥144,067,000 | ¥317,017,000 | ¥230,059,000 |
| % Margin | 2.4% | 3.4% | 7.9% | 6.4% |
| EPS Diluted | 67.23 | 91.16 | 201.94 | 145.87 |
| % Growth | -26.3% | -54.9% | 38.4% | – |
| Operating Cash Flow | ¥962,493,000 | ¥640,321,000 | ¥877,217,000 | ¥1,021,218,000 |
| Capital Expenditures | -¥200,795,000 | -¥175,420,000 | -¥140,657,000 | -¥123,252,000 |
| Free Cash Flow | ¥761,698,000 | ¥464,901,000 | ¥736,560,000 | ¥897,966,000 |